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Abstract
Polymeric particles are a versatile class of local or systemic drug delivery systems, used to improve drugs
pharmacokinetics and pharmacodynamics along with patient compliance. Herein, we report a rapid,
scalable, and optimized method to encapsulate ciprofloxacin (CPx), a poor water soluble antimicrobial
agent, in gelatin microparticles by single step processing via spray-drying of an aqueous solution. The
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encapsulated drug is released during the first 6 h, and the release kinetics was best fitted with the
Korsmeyer-Peppas model, explained by the superimposition of drug diffusion and polymer chain
relaxation. The minimal inhibitory concentrations against S. aureus and E. coli, obtained from pure and
encapsulated ciprofloxacin, demonstrated that the spray-drying process does not inhibit the drug's
bioactivity or the process feasibility. Thus, spray-drying of protein-drug particle systems is an
advantageous method to produce microparticles with potential to lung delivery systems.
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Abstract:
Polymeric particles are a versatile class of local or systemic drug delivery systems, used
to improve drugs pharmacokinetics and pharmacodynamics along with patient
compliance. Herein, we report a rapid, scalable, and optimized method to encapsulate

PT

ciprofloxacin (CPx), a poor water soluble antimicrobial agent, in gelatin microparticles
by single step processing via spray-drying of an aqueous solution. The developed

RI

particles show mainly a wrinkle morphology with a unimodal distribution, with mean

SC

diameters ranging between 2 and 4 𝜇𝑚, depending on the processing conditions. The
encapsulation of 1, 2 and 5 wt% CPx narrows the size distribution (1-3 𝜇m). In vitro

NU

release experiments showed that up to 80% of encapsulated drug is released during

MA

the first 6 hours, and the release kinetics was best fitted with the Korsmeyer-Peppas
model, explained by the superimposition of drug diffusion and polymer chain

D

relaxation. The minimal inhibitory concentrations against S. aureus and E. coli,

PT
E

obtained from pure and encapsulated ciprofloxacin, demonstrated that the spraydrying process does not inhibit the drug`s bioactivity or the process feasibility. Thus,

CE

spray-drying of protein-drug particle systems is an advantageous method to produce

AC

microparticles with potential to lung delivery systems.
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1. Introduction
Particulate systems are a class of drug delivery systems of great clinical and research
interest for both local and systemic delivery, which are designed to improve drug
bioavailability, stabilization, pharmacokinetics and selectivity, while avoiding toxicity

PT

issues raised by added excipients, continuous administration or tissue accumulation [1,
2]. Those systems are particularly appealing for pharmaceutical industry due to their

RI

versatility, enabling topical, pulmonary, nasal or parenteral administration [2, 3] in

SC

creams [4], hydrogels [5], dry powders and aerosols [6, 7] or injectable formulations
[8].

NU

Drug loaded polymeric particles fabrication often rely on drying of a droplet containing

MA

the formulated mixtures from dissolved, dispersed or emulsified substances [9, 10].
Most relevant techniques include spray-drying [7, 11], spray freeze drying [12], and

D

electrospray [13], among others. Spray-drying is a well-established technology in the

PT
E

pharmaceutical and food industry, for microencapsulation [14, 15]. This a continuous,
single step, cost-effective and scalable technique that allows for the tuning of the final

CE

particles properties [9, 16] and for the processing of heat sensitive molecules
(proteins, peptides or drugs) which, in turn, enhance the bioactivity of the final

AC

formulations [17, 18]. This is due to the fast solvent evaporation of droplets with high
surface area-to-volume ratio [18]. Furthermore, the encapsulation of hydrophobic
molecules is also possible by the atomization of emulsified feed solution, introducing
then an extra processing step [19, 20].
Natural polymers are often a smart choice when developing medical devices mainly
due to their biocompatibility and biodegradability. Gelatin is a natural biopolymer,
with a wide set of applications in the food, pharmaceutical and cosmetic industries,
3
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since it is considered as a GRAS (generally recognized as safe) material by the FDA [21].
Despite its animal source, toxicity and antigenicity issues are minimal due to acid/alkali
hydrolysis of collagen during processing [21, 22]. Other attractive features of gelatin
for drug delivery systems include the available functional groups for the coupling of

PT

ligands, targeting or the stabilization by crosslinking, increasing circulation times [21].
In this work, an alternative source of gelatin – fish gelatin – was chosen, which,

RI

considering the targeted application, would reduce the concerns about prion

SC

transmission related with animal sources of gelatin [23].

Ciprofloxacin (CPx) is a broad-spectrum fluoroquinolone antibacterial agent indicated

NU

for the treatment of acute cystitis, chronic prostatitis, urinary and lower respiratory

MA

tract infections, acute sinusitis, skin infections, bone and joint infections, among others
[24]. It is also administered to treat opportunistic Pseudomonas aeruginosa in cystic

D

fibrosis patients [24]. CPx acts by inhibition of bacterial DNA gyrase and topoisomerase

PT
E

IV that disrupts bacterial DNA replication [25]. Side effects associated with CPx use,
including gastrointestinal, cardiovascular and allergic reactions and nervous system

CE

complaints [26], along with its poor water solubility and bioavailability [24, 27]
motivates the development of effective encapsulations systems.

AC

This work reports the development and optimization of gelatin microparticles for CPx
encapsulation using an orthogonal design by a single-step procedure using spraydrying. The developed microparticles were characterized by SEM, FTIR and thermal
analysis and the in vitro release profile was fitted to the mathematical release models.
The crosslinking effect (glutaraldehyde) on the microparticle diameter was also
evaluated. CPx bioactivity was assessed by determining the minimal inhibitory and

4
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bactericidal concentrations against susceptible strains of E. coli (Gram-negative) and S.

AC

CE

PT
E

D

MA

NU

SC

RI

PT

aureus (Gram-positive) comparing the CPx-loaded microparticles with the free drug.
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2. Material and methods
2.1. Materials
Gelatin (gel) from cold water fish skin, glutaraldehyde solution (GA; 50 wt.%) and
ciprofloxacin (CPx; ≥ 98.0%) were supplied by Sigma-Aldrich. All reagents and

PT

chemicals used were of analytical grade.

RI

2.2. Polymer particle processing

SC

Gel solutions were prepared in double distilled water (ddH2O) at different

room temperature (25ºC) before use.

NU

concentrations (0.5, 1 and 2 % w/v) under magnetic stirring at 50 ºC and cooled to

MA

For gel-CPx formulations, a stock solution of CPx in 0.1N HCl was prepared separately
and added to a gel solution (0.5 % w/v) for a final CPx concentration of 1, 2 and 5 wt%.

D

Spray-drying was performed using a home-made system (figure 1). The experimental

CE

detailed in Table 1.

PT
E

parameters range for gelatin concentration, feed rate and inlet temperature are

2.3. Experimental design

AC

The influence of the processing parameters on gel microparticles produced by spraydrying was evaluated by an orthogonal design table 𝐿9 , using Orthogonal Design
Assistant II software (Sharetop Software Studio). Each orthogonal table has its own
mark denoted as (1):
𝐿𝑛 (𝑡)𝑐

(1)

where 𝐿 represents the orthogonal table of 𝑛 experiments, 𝑡 is the number of levels of
each factor and 𝑐 is the maximum number of factors. To produce gel microparticles the
6
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defined factors of polymer concentration (A), feed rate (B) and inlet temperature (C),
their levels and the experimental set up for the nine experimental conditions (A-I) are
describe in Table 1.
The selection of optimal conditions was based on the orthogonal parameters K and R,

PT

which were calculated from the particle diameters as:

RI

∑ 𝑒𝑣𝑎𝑙𝑢𝑎𝑡𝑖𝑜𝑛 𝑖𝑛𝑑𝑒𝑥𝑒𝑠 𝑎𝑡 𝑠𝑎𝑚𝑒 𝑙𝑒𝑣𝑒𝑙 𝑜𝑓 𝑒𝑎𝑐ℎ 𝑓𝑎𝑐𝑡𝑜𝑟
3

SC

𝐾𝑙𝐹 =

(3)

NU

𝑅 𝐹 = 𝑚𝑎𝑥{𝐾𝑙𝐹 } − 𝑚𝑖𝑛{𝐾𝑙𝐹 }

(2)

MA

where 𝐾 and 𝑅 represents the mean and range values, respectively, for a factor 𝐹 at
the level 𝑙 [28, 29]. The impact of the three factors (gel concentration, feed rate and

D

inlet temperature) on the average particle diameter was evaluated by investigating the

PT
E

influence of different levels of each factor [28]. The determination of the factors order

2.4. Rheology

CE

was achieved by calculating the range (𝑅) for each factor upon evaluation indexes (𝐾𝑖 ).

AC

The rheological behavior of gel solutions with different protein concentrations (0.5, 1
and 2 % w/v) were evaluated using a parallel plate (∅ = 20 𝑚𝑚) geometry rheometer
(MCR 301, Anton Paar) with a 0.3 mm gap to ensure adequate filling of the samples
over the testing disk. Viscosity was measured as a function of shear rate within the
range of 1-1000 s-1, at 25 ºC.

7
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2.5. Polymer particles crosslinking
Dry particles were crosslinked using 20 mL of a glutaraldehyde solution (50 % in H 2O,
Sigma-Aldrich) in the vapor phase, in a vacuum chamber (VACUO-TEMP, JP Selecta,

PT

Spain), at room temperature, and under low pressure for 72 h.

2.6. Particles characterization

RI

Particles were coated with a thin gold layer using a sputter coater (Smart Coater, JEOL)

SC

and their morphology was analyzed using a scanning electron microscope (JCM6000PLUS Neoscope, JEOL), with an accelerating voltage of 10 kV. Particles average

NU

diameter and its distribution was calculated over 300 particles in SEM images (1,000 x

MA

magnification) using the Image J software [30]. Particles dispersity was quantitatively
evaluated by the coefficient of variation (𝐶𝑉 ), defined as:
𝜎
𝜇

(4)

PT
E

D

𝐶𝑉 =

where 𝜎 represents the standard deviation of the mean particle size (𝜇) [31].

CE

Infrared (FTIR) measurements were performed in a Shimadzu IRAffinity-1S apparatus

AC

in ATR mode from 4000 to 600 cm-1, at room temperature. FTIR spectra were collected
after 32 scans with a resolution of 2 cm-1. Differential scanning calorimetry (DSC)
measurements were performed with a TA Q100 apparatus (TAinstruments), between
30 and 200 ºC at a heating rate of 10 ºC.min-1, under a nitrogen purge.
Thermogravimetrical

analysis

(TGA)

was

conducted

in

a

Q500

apparatus

(TAinstruments) using a heating rate scan of 20 ºC min-1, under a nitrogen atmosphere.

8
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2.7. Determination of CPx loading
The CPx loading was determined by dissolving the dry gel-CPx microparticles in 0.1 M
HCl, in ultrasonic bath for 6 h followed by mechanical stirring at 37 ºC. After 72 h, the
suspensions were centrifuged (10,000 rpm, 10 min) to remove polymeric debris and

PT

the CPx was measured in the supernatants using a spectrophotometer (Shimadzu
UV1800), using crosslinked drug-free gel particles as blank controls. The drug loading

RI

was calculated per equation 5, using a calibration curve of CPx in 0.1 M HCl (equation

SC

6) at 𝑂𝐷 = 277 𝑛𝑚, where 𝑥 is the drug concentration (𝜇𝑔/𝑚𝐿) and 𝑅 2 is the

NU

coefficient of determination.

MA

𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐶𝑃𝑥 𝑖𝑛 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
× 100
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠

D

𝐷𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (%) =

(6)

PT
E

𝑂𝐷277𝑛𝑚 = 0.1245𝑥 + 0.004768 (𝑅 2 = 0.999)

(5)

CE

2.8. In vitro CPx release

AC

Gel-CPx suspensions (10 mg mL-1; 5 mL) were transferred to a tubular dialysis
membrane with a MWCO of 1 kDa (Cellu.Sep H1, Fisher Biotec). The membranes were
then immersed in 200 mL of PBS (pH 7.4), under smooth magnetic stirrer (100 rpm) at
37 ºC. At predetermined time intervals, 2 mL of the release medium was withdrawn
and replaced with fresh PBS. The release medium was measured at 𝑂𝐷 = 270 𝑛𝑚
using a UV-VIS spectrophotometer (Shimadzu UV1800) and the CPx amount was
calculated using a calibration curve in PBS (7), where 𝑥 is the drug concentration

9
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(𝜇𝑔/𝑚𝐿) and 𝑅 2 is the coefficient of determination. Results were expressed as %
cumulative release relative to the initial weight of CPx loaded in the particles. Analysis
was performed in triplicates and results were averaged.

𝑂𝐷270𝑛𝑚 = 0.09847𝑥 + 0.001677 (𝑅 2 = 0.998)

PT

(7)

RI

The experimental results were fitted to the first order (8), Higuchi (9) and Korsmeyer-

SC

Peppas (10) models to further evaluate the release kinetics.

NU

log 𝐶 = 𝑙𝑜𝑔𝐶0 − 𝐾𝑡/2.303

MA

𝑀𝑡
= 𝐾 √𝑡
𝑀∞

D

𝑀𝑡
= 𝐾𝑡 𝑛
𝑀∞

(8)

(9)

PT
E

(10)

CE

where 𝐶 and 𝐶0 are, respectively, the cumulative and initial amounts of drug, 𝑀𝑡 /𝑀∞
is a fraction of drug released at time 𝑡, 𝐾 is the rate constant, and 𝑛 is the exponent

AC

that characterizes the release mechanism [32, 33].

2.9. Determination of the antibacterial activity of Gel-CPx particles
The susceptibility of Staphylococcus aureus (ATCC29213) and Escherichia coli
(NCTC8196) to the gel-CPx (5 wt%) microparticles was evaluated by broth
microdilution assay as previously described, with slight modifications [34]. Briefly,
bacteria were streaked from glycerol-frozen stocks onto Luria-Bertani Agar (LB;
10
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tryptone 10 gL-1, yeast extract 5 g L-1, NaCl 10 g L-1, agar 15 g L-1, pH 7.4) plates and
incubated overnight at 37 ºC. Overnight cultures of S. aureus and E. coli were prepared
from single colonies in Brain-heart infusion (BHI; 37 g L-1, pH 7.4) or LB broths,
respectively, at 37 ºC in an orbital shaker (160 rpm).

PT

Dry formulations of gel (uncross- and crosslinked) and gel-CPx (5 wt%) microparticles
(crosslinked) were sterilized prior to incubation by UV exposure for 25 min. To ensure

RI

sterility of UV-irradiated samples, 100 µL of stock solutions was plated in LB agar and

SC

blood-agar media and monitored for bacterial growth. CPx concentration in
formulations was calculated per the percentage of drug entrapment. Controls of pure

NU

CPx were prepared from a stock solution (30 µg mL-1) in PBS (pH 7.4) and sterilized by

MA

filtration. All experimental formulations were then 2-fold serially diluted in 100 𝜇l of
culture medium to reach the tested concentrations. Each well was then inoculated
100

𝜇L

of

bacterial

suspension

containing

D

with

PT
E

1𝑥106 𝐶𝐹𝑈 (𝑐𝑜𝑙𝑜𝑛𝑦 𝑓𝑜𝑟𝑚𝑖𝑛𝑔 𝑢𝑛𝑖𝑡𝑠) 𝑚𝐿−1 .
Bacterial cultures were then incubated for 18-20 h at 37 ºC and the minimum

CE

inhibitory concentration (MIC) was determined as the lowest concentration with clear
wells, using a microplate reader (SpectraMax Plus 384, Molecular devices, USA) at

AC

OD600 nm. Minimum bactericidal concentration (MBC) was determined by plating 10 µL
of each well with growth inhibition (clear wells) on LB agar medium. Following
incubation for 24 h at 37 ºC, MBC was determined as the lowest concentration where
bacterial growth was absent.

11
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2.10. Data analysis
Quantitative data are presented as mean ± standard deviation (SD). Significant
differences were determined by one-way ANOVA analysis with Tukey`s HSD post hoc

PT

test using GraphPad Prism Software (v 6.01). Statistical differences were considered

SC

RI

when 𝑝 < 0.05.

3. Results and discussion

NU

3.1. Optimization of gelatin microparticles

The average particle diameter was the measured response of the orthogonal design to

MA

produce gel microparticles by spray-drying technique, in a single step, avoiding
intermediate steps, such as emulsification. Results of average particle diameter,

PT
E

D

coefficient of variation and orthogonal indexes are presented in table 2, for the
experimental runs from A to I (table 1). The larger the 𝑅 parameter, the more
influence of the factor on the process, reflecting either valuable or detrimental effects

CE

[28, 29, 35, 36]. For the processing of gel microparticles by spray-drying, gelatin

AC

concentration is the most important factor followed by the feed rate and the inlet
temperature (𝐴 > 𝐵 > 𝐶). Figure 2 depicts the influence of tested factors and levels
on the average particle diameter and coefficient of variance. Despite the narrow
diameter range of the experimental runs (between 2.62 ± 0.78 and 3.65 ± 1.17 𝜇𝑚), it
can be pointed out a concentration-dependent increase in particle diameter (figure 2a)
that can be mainly addressed to the increased viscosity of the feed solution (figure 2b).
Differences in the rheological behavior of gelatin solutions are obvious between the

12
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lower (0.5 and 1 % (w/v)) and the highest concentration (2 % (w/v)); the first ones
showed a typical Newtonian behavior, whereas the 2 % (w/v) solution behave as a
shear thinning fluid. For instance, for lower shear rates the difference in the viscosity is
up to 7 times for the 2 % (w/v) solutions (figure 2b – inset). The relationship between

PT

feed solution concentration and particle size has been reported by Elversson et al. for
lactose powders, where the increase in concentration lead to larger particles, although

RI

the effect was not linear [37].

SC

The influence of the tested factors and levels on the particles dispersity, quantitatively
evaluated by the 𝐶𝑉 , were almost negligible, and similar values were found for all

NU

experimental runs, and all below 0.5 (table 2). The water content in dry formulations is

MA

of outmost importance for the formulation preservation and for the improvement of
shelf-life [38]. The overall variation in the moisture content for the orthogonal

D

experiments (figure S1) was less than 2 % and, therefore, it is not influenced by the

PT
E

studied levels.

The selection of the optimal combination is determined by the smallest index and, for

CE

this work consisted of a feed concentration of 0.5% (w/v), using a feed rate of 308 ml
h-1 at 115ºC. However, the optimal feed rate had to be adjusted for the subsequent

AC

experiments to the following level (177 ml h-1) due to the moisture introduced in the
sample collector, that dissolved the formed particles and leading to a non-continuous
processing.
The samples collected after spray-drying presented a mixture of wrinkled (mostly) and
a few smooth spherical particles, as depicted in figure 3, following a unimodal
distribution (figure 4), in accordance with the lower 𝐶𝑉 values (table 2). Irregular
particle morphology was already reported for gelatin microspheres [19], and is usually
13
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associated with high Peclet numbers, which relates convection and diffusion
phenomena and is influenced by the solvent evaporation rate [16]. Nevertheless,
wrinkle-shaped albumin particles showed better performance in aerosolization studies

PT

due to its lower contact area that decreases the powder cohesiveness [39].

3.2. Characterization of Gel-CPx particles

RI

Ciprofloxacin (CPx)-loaded gelatin microparticles were produced by single-step spray-

SC

drying following the best experimental conditions determined in section 3.1. The gel
crosslinking was performed in the vapor phase to improve particle stability, while

NU

diminishing possible cytotoxic effects associated with the crosslinking agent (GA) [19,

MA

40]. Both uncross and crosslinked particles obtained by spray-drying presented a
wrinkled surface morphology (figure 5 a – d) like the ones observed in the orthogonal

D

experiments (figure 3). Overall, the presence of CPx induced a narrower particle size

PT
E

distribution (figure 5 e - f), presenting a higher impact on the particle size rather than
the crosslinking itself. Statistical differences were found between uncross and

CE

crosslinked samples only for 0 and 1 % wt CPx. It was reported that the use of GA as a
crosslinking agent for gelatin, did not changed significantly the sample fiber diameter

AC

[41, 42]. Furthermore, the moisture content for the CPx-loaded formulations (figure
S2) was comparable to the drug free ones.
Average diameters for CPx-loaded particles ranged from 2.73 ± 0.84 𝜇𝑚 to
2.93 ± 0.86 𝜇𝑚 for the uncrosslinked samples, and from 2.61 ± 0.70 𝜇𝑚 to
2.79 ± 0.80 𝜇𝑚 for the crosslinked ones. The crosslinking also lowered coefficient of
variation, except for the highest CPx concentration.

14
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Considering the optimal particle size for the lung administration of small molecules,
the obtained particle size shows potential to target the alveolar region. It was reported
that particles in the narrow window of 1 – 5 m, behave more like gas molecules and
follow airflow all the way to the alveoli by a number of mechanisms, including

PT

diffusion, sedimentation, and electrostatic effects [43]. Particles in the range size of 1 –
3 𝜇m are in peak of alveolar deposition [6, 44-46].

RI

CPx loading was carried out according to the procedure detailed in the experimental

SC

section, and the efficiency achieved was above 94 % (Table 3). Spray-drying of an
aqueous solution of gelatin proved to be suitable to incorporate CPx, and thus,

NU

avoiding the incorporation of any other organic solvents in the mixture, being also

MA

environmentally friendly.

The infrared spectrum of pure CPx, gel and gel-CPx (5 %wt.) particles is depicted in

D

figure 6. The protein characteristic absorption bands were observed both in gel and

PT
E

gel-CPx particles at approximately 1650 cm-1 (amide I), 1540 cm-1 (amide II) and 1240
cm-1 (amide III), corresponding to the stretching vibrations of C=O bond, to the

CE

coupling of bending of N-H bond and stretching of C-N bonds, and to the stretching of
C-N bonds plus the in-phase bending of N-H bonds, respectively [47, 48]. It was

AC

possible to observe the CPx absorption band at 1284 cm-1, assigned to the C-N
stretching [49], in the microparticles FTIR spectra, confirming its presence in the drugloaded particles. Moreover, it can be observed that the particle processing does not
suppress totally any absorption modes nor new vibrational modes seem to appear
suggesting the absence of covalent bonds between gelatin and the drug.

3.3. Thermal analysis
15
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DSC curves of microparticles and free CPx are reported in figure 7a. CPx showed to be
stable within the range of the processing temperatures. DSC data recorded for the
pristine gelatin and gelatin loaded with CPx, showed similar trends, suggesting that the
spray dry process does not influence the polymer thermal properties. A broad

PT

endothermic peak at lower temperatures, between 30 – 120 ºC was attribute to the
volatilization of absorbed and unbonded water present in the gelatin particles (figure

RI

7a). The presence of water molecules in the particles is probably due to the storage

SC

and handling of the sample, at room conditions. Gelatin is a hygroscopic protein, and
can trap up to 12 wt% of water from moisture [50, 51]. The characteristic helix-coil

NU

transformation of gelatin was detected at ~190 ºC [52]. Moreover, the enthalpy of the

MA

helix -coil decrease from 15.9 J g-1 for the pristine gelatin samples, down to 1.9 J g-1 for
the sample loaded with 5 wt% of drug. These results suggest that the presence of CPx

D

alters the formation of the characteristic helical structure, probably disrupting the

PT
E

hydrogen bonds between the polymer chains, by creating new hydrogen interactions
between hydroxyl groups and amides present in both, drug and in the polymer chains

CE

[53]. Peña et al. reported that the incorporation of tannin in gelatin films, led to a
decrease of the enthalpy of the helix-coil structure, from 15 J.g-1, calculated for pristine

AC

gelatin films, down to 3 J g-1, for a sample with 30 wt% tannin [53]. This behavior was
attributed to the tannin ability to modify the hydrogen bonding between the protein
chains, and creation of new hydrogen interactions between the tannin hydroxyl groups
and gelatin polar groups.
Thermogravimetric analysis was performed to the prepared unloaded and loaded
gelatin particles. Two different weight loss steps can be distinguished in figure 7b. The
first one, between room temperature and 120 ºC, attributed to the loss of water
16
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absorbed during sample storage and handling [50, 53]. The second degradation step,
that occurred between 250 – 400 ºC, was attributed to the protein helix structure
chain breakage, and peptide bonds rupture [53, 54]. The residual weight of the protein

PT

(≈35 wt%) agrees with the values reported in literature [54, 55].

3.4. In vitro release studies

RI

The cumulative in-vitro release of CPx carried out at physiological pH is depicted on

SC

figure 8a. All tested formulations presented a similar release profile where the
complete release was achieved within 24 hours. The release profiles of the gel-CPx

NU

microparticles with different amounts of drug showed a burst release within the first 6

MA

hours, followed by a slower release rate (figure 8a).

Gelatin particles can be seen as a polymeric network swollen with solvent, where the

D

water fills the space between the strands of the polymer chains [56, 57], and act as

PT
E

permeation channels. When the drug loaded particles are immersed in the release
media, the polymer is capable to uptake the water based media, followed by

CE

relaxation of the macromolecular chains and volume expansion, and the CPx drug can
diffuse to the external receptor medium from within the gelatin microparticle. The

AC

suggested mechanism for the CPx release is presented in figure 8b.
The obtained release profiles of the gelatin microparticles were in between of some
gelatin systems reported in literature obtained via emulsion and desolvation
techniques. The developed system had a more sustained release over time than a
paclitaxel-loaded system with 90 % release in 2 h [58], but a faster release compared
with methotrexate-gelatin nanoparticles with a release profile over 150 h, depending
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on drug-gelatin ratio, and amount of poly(methyl methacrylate) present in the oil
phase, during the preparation of the emulsion [56].
The release profile was further investigated, and the experimental data was modelled
to the first order, Higuchi and Korsmeyer-Peppas (KP) models, and the kinetic

PT

parameters are presented in table 4. The best fittings were obtained for first-order and
KP models with coefficients of determination higher than 0.98.

RI

Despite having similar profiles, the calculated release rate tends to increase with the

SC

increasing of drug loading in the system, an effect already reported [56]. According to
KP model, a statistically significant increase in release rate was obtained between 1

NU

wt.% and 2 wt.% formulations, which could be due to the high distance that the drug

MA

must travel from the core of the polymeric particle to the release medium, and
consequently decreasing the release rate. However, no significance was obtained

D

between those formulations and the 5 wt.% ones, being more similar to the 2 wt.%,

PT
E

which indicates that for contents above 2 wt.% the release rate is not influenced by
spatial effects.

CE

Berkland et al. [59] reported the effect of particle size (10 to 100 𝜇m) on drug release
kinetics but such effect cannot be attributed to this gel-CPx system since the mean

AC

diameter differences are almost negligible (figure 5 - f). Thus, differences in 𝑘 values
can be mainly addressed to geometrical factors, since particles having smaller drug
loadings provide a larger path to the drug molecules to reach the release media (figure
8b).
Drug release from a polymeric system can be due to relaxation of the polymer chains
over time, resulting in additive movement out of the polymer matrix; due to diffusion,
where the drug moves out of the polymer matrix due to a concentration gradient
18
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within the polymer, or degradation controlled, where part of the polymer dissolves in
the release medium which causes the release of the drug present in that part of the
polymer network [60, 61]. For the spray dried gelatin microparticles, drug release due
to erosion of the polymer matrix is unlikely, as crosslinked gelatin does not dissolve

PT

under existent experimental conditions and its biodegradation starts at a time longer
than that taken into consideration [50]. Thus, the mechanism of CPx release could be

RI

either diffusion or relaxation controlled, and can be elucidated by the value of the

SC

diffusion exponent (n) predicted by the KP model (equation 10). The value of n,
summarized in table 4, suggests that a n value between 0.69 up to 0.75, and therefore,

NU

the release of CPx may be considered as an anomalous transport and indicate a

MA

superimposition of the two mechanisms - drug diffusion and polymer chain relaxation

D

(0.43 < n < 0.85, for spherical systems) [32].

PT
E

3.5. MIC and MBC determination for CPx-loaded particles
The bioactivity of released ciprofloxacin was investigated by determining the minimal

CE

inhibitory and bactericidal concentrations against susceptible strains of E. coli (Gramnegative) and S. aureus (Gram-positive). The dose-dependent curves of bacterial

AC

growth (figure 9) and MIC/MBC values (table 5) showed similar growth profiles for
pure or encapsulated CPx for both bacteria. Unloaded gel particles (uncross- and
crosslinked with GA) did not affect bacterial growth, mitigating any possible influence
of GA in the MIC values. MIC and MBC values determined against S. aureus and E. coli
were comparable for pure or encapsulated drug. Experimental MICs were consistent
with those reported in literature for ciprofloxacin against non-resistant strains of S.
aureus [7, 62-64] and E. coli. [62-65]. These results confirm the biological function of
19
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ciprofloxacin after processing by spray-drying and suggest that the process does not
induce any adverse effects on the structure of ciprofloxacin.

PT

4. Conclusions
This work reports a facile and fast method of producing gelatin microparticles loaded

RI

with ciprofloxacin, a poorly water soluble antibacterial agent, with great potential for

SC

scale-up. Gelatin-ciprofloxacin particles with mean diameter between 2 and 3 𝜇𝑚 were
developed by single step procedure, with loading efficiencies above 94% and an in

NU

vitro release profile over the first 6 hours. Loaded ciprofloxacin activity was

MA

demonstrated against S. aureus and E. coli, showing MIC and MBC values comparable
to the pure CPx.

D

Spray-drying of protein-drug particle systems could be an advantageous alternative to

PT
E

emulsions, providing higher production rates, and given their features might have

CE

potential to lung administration of drugs.
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Figure Captions:

Figure 1 – Spray dry apparatus used in the production of the gelatin microparticles.

Figure 2 – a) Relationship between the average particle diameter (black) and

PT

coefficient of variation (red) and the factors and levels of the orthogonal experimental

RI

design, and b) Viscosity of gelatin solutions (0.5, 1 and 2 % w/v) as a function of shear

SC

rate at 25ºC; inset: viscosity dependence on gelatin concentration at a shear rate of 10

NU

s-1.

Figure 3 – Morphology of gelatin particles obtained at experimental processing

MA

conditions from A to I analyzed by SEM.

PT
E

D

Figure 4 – Particle (conditions A to I) diameter distribution obtained from, at least, 300
particles/sample using ImageJ software.

CE

Figure 5 – Morphology of gelatin microparticles obtained by SEM analysis: (a) un-

AC

crosslinked gel-CPx 0 % wt, (b) crosslinked gel-CPx 0 % wt., (c) un-crosslinked gel-CPx 5
% wt., (d) crosslinked gel-CPx 5 % wt. Size distributions (e) and average diameter (f) for
un-crosslinked (dash) and crosslinked (line) gel-CPx formulations (0, 1, 2 and 5 %wt).
Inset: coefficient of variation (𝐶𝑉 ) for the formulations. * represents differences by
comparison with each control (un-crosslinked) and § represents comparisons between
formulations (*p< 0.05; ****p<0.0001; §§§§p <0.0001; ns: non-significant).
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Figure 6 – Fourier transformed infrared spectra of pure ciprofloxacin (CPx) and gelatin
particles with 0 and 5 wt% of CPx.

Figure 7 – Thermal analysis of pure CPx and gel-CPx particles: (a) differential scanning

PT

calorimetry and (b) thermal degradation profile of recorded at 20 °C.min-1.

RI

Figure 8 – a) In vitro release of ciprofloxacin (CPx) from gel-CPx formulations with

SC

different loadings. Experiments were performed in triplicates in PBS buffer (pH 7.4) at

NU

37 ± 0.5 ℃; b) proposed release mechanism for CPx.

Figure 9 – MIC measurements for pure ciprofloxacin (CPx) and gel-CPx formulations

MA

against S. aureus and E. coli. Unloaded gelatin particles uncross (gel-uncross) and

AC

CE

PT
E

D

crosslinked with glutaraldehyde (gel-cross) were used as controls.
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Table Captions:
Table 1 – Factors (A, B and C), levels (1, 2 and 3) and experimental conditions of

PT

Orthogonal experimental design 𝐿9 (3)4 for producing gelatin microparticles by spray-

SC

RI

drying.

NU

Table 2 –Diameter and coefficient of variation (CV) of gelatin particles and orthogonal

MA

indexes calculated from particles diameter.

PT
E

D

Table 3 – Ciprofloxacin loading (%) in gelatin particles calculated by UV-VIS analysis.

CE

Table 4 – Kinetic parameters for first order, Higuchi and Korsmeyer-Peppas models
determined from fitting of release experiments for the three formulations of gel-CPx

AC

particles.

Table 5 – Comparison of MIC and MBC values for pure ciprofloxacin and gel-CPx
formulations against S. aureus and E. coli using broth microdilution test. Results are
expressed as mean standard deviation of three independent experiments.
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Table 1
Factors
B (ml h-1)

C (ºC)

1

0.5

90

115

2

1

177

130

3

2

308

140

Levels
1

1

B

1

2

C

1

D

2

E

2

F

2

G

3

D

MA

NU

SC

A

3

PT
E

H

3

AC

CE

I

RI

Experiment

32

PT

A (% w/v)

Levels

1
2

3

3

2

1

1

3

3

2

1

2

2

3

3

1
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Table 2
Diameter ± SD (µm)

CV

A

2.63 ± 0.71

0.27

B

2.76 ± 0.75

0.27

C

2.62 ± 0.78

0.30

D

2.80 ± 1.09

0.39

E

3.14 ± 1.02

0.32

F

2.83 ± 1.05

0.37

G

3.65 ± 1.17

H

3.57 ± 1.33

I

3.25 ± 1.32

RI
SC

0.32

NU

0.37
0.40

B

C

(Concentration)

(Feed rate)

(Inlet temperature)

𝐾1

2.668

3.139

2.894

𝐾2

2.925

3.045

3.081

3.492

2.901

3.110

0.824

0.237

0.217

PT
E

D

Indexes / Factors

𝐾3

𝐴>𝐵>𝐶

CE

Range 𝑅
Order

MA

A

PT

Experimental runs

Optimal combination

AC

𝐴1 𝐵3 𝐶1
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Table 3
Drug loading (%)

Efficiency (%)

Gel-CPx 1 wt.%

1.0±0.03

100

Gel-CPx 2 wt.%

1.95±0.37

97.5

Gel-CPx 5 wt.%

4.73±0.44

94.6

AC

CE

PT
E

D

MA

NU

SC

RI

PT

Samples
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Table 4
First Order

s

k

Korsmeyer-Peppasa

Higuchi
R2

kH

R2

0.98

33.99±3.69n

0.98

0.25±0.07*

1%

0.49±0.01n

n

R2

0.69±0.0

0.99

4

9

0.75±0.0

0.99
8

k

35.00±4.35*
6

s

4

0.98

43.46±5.12n

0.94

PT

Formulation

52.61±7.76*

0.54±0.07

s

4

6

0.99

40.14±0.62n

0.96

50.16±3.12n

0.70±0.0

0.99

8

s

3

s

1

3

*

NU

5%

6

SC

s

RI

2%

a

*

MA

calculation of kinetic parameters considered values below 60% release, following model assumptions
[32]
denotes statistically differences between marked formulations (𝑝 < 0.05)
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Table 5

MIC (𝜇𝑔/𝑚𝑙)

MBC (𝜇𝑔/𝑚𝑙)

E. coli

S. aureus

E. coli

Pure CPx

0.25

0.008

0.667±0.236

0.011±0.004

Gel-CPx

0.25

0.008

0.417±0.118

0.036±0.019

AC

CE

PT
E

D

MA

NU

SC

RI

PT

S. aureus
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A single step method to produce gelatin-ciprofloxacin microparticles is
presented.
Spray-drying led to microparticles with suitable diameters for lung
administration.
80 % of the encapsulated drug is released over 6 h, with MIC like the free drug.
This scalable method shows potential for dry systems in pharmaceutical
industry.
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